Soleno TherapeuticsSLNO
Market Cap: $1.89B
About: Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
Employees: 42
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
80% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 25
67% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 10 (+4) [Q2]
26% more capital invested
Capital invested by funds: $1.52B [Q1] → $1.92B (+$392M) [Q2]
19.15% more ownership
Funds ownership: 109.8% [Q1] → 128.95% (+19.15%) [Q2]
16% more funds holding
Funds holding: 98 [Q1] → 114 (+16) [Q2]
92% less call options, than puts
Call options by funds: $1.3M | Put options by funds: $15.6M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target | 44%upside $70 | Buy Initiated | 3 Sept 2024 |
Oppenheimer Leland Gershell 55% 1-year accuracy 27 / 49 met price target | 34%upside $65 | Outperform Maintained | 12 Aug 2024 |
Cantor Fitzgerald Kristen Kluska 59% 1-year accuracy 48 / 81 met price target | 38%upside $67 | Overweight Reiterated | 31 Jul 2024 |
Financial journalist opinion
Based on 4 articles about SLNO published over the past 30 days